SCHEMBL23905574

SCHEMBL23905574

COc1cc(Oc2nc3cc4[nH]ncc4cc3c(-c3ccc(F)cc3)c2C(C)C)ccc1C(O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.37
DRD1 P21728 3/20 0.35
TLR8 Q9NR97 2/20 0.32
TLR9 Q9NR96 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
FLT3 P36888 1/20 0.32
FGFR2 P21802 3/20 0.32
FGFR1 P11362 2/20 0.32
TRPA1 O75762 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MAOB P27338 1/20 0.31
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25488576 0.91 DRD1 (0.35) MKNK1DRD1FGFR2FGFR1TRPA1
SCHEMBL25475040 0.87 NPC1 (0.39) MKNK1DRD1KDM4ENPC1LMNA
SCHEMBL30252031 0.81 RXRA (0.43) NPC1RAB9AMAPK1
SCHEMBL23884399 0.81 RXRA (0.43) NPC1RAB9AMAPK1
SCHEMBL23906136 0.81 MIF (0.36) DRD1NPC1RAB9AROCK1MAPK1
SCHEMBL30251795 0.80 MKNK1 (0.37) MKNK1MAOBNPC1RAB9ASMN1; SMN2
SCHEMBL23884496 0.80 MKNK1 (0.37) MKNK1MAOBNPC1RAB9ASMN1; SMN2
SCHEMBL23905576 0.77 CHEK2 (0.37) MKNK1FGFR2MAOBNPC1LMNA
SCHEMBL23905579 0.77 FGFR2 (0.35) MKNK1FGFR2FGFR1NPC1RAB9A
SCHEMBL23884493 0.77 STK17A (0.43) MKNK1FGFR2FGFR1ROCK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed